Gastrointestinal cancers encompass the esophagus, stomach, bowel and rectum, liver, and pancreas.

The Gastrointestinal Disease Site Group (GI- DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. The titles of the reports produced to date by the GI DSG are listed below, together with links to the PDF versions of those reports.

Colorectal Cancer

  • Preoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer
    EBS #2-4: July 2008

    EBS #2-4 replaces Practice Guidelines #2-3 Postoperative Adjuvant Radiotherapy and/or Chemotherapy for Resected Stage II or III Rectal Cancer and #2-13 The Use of Preoperative Radiotherapy in the Management of Patients with Clinically Resectable Rectal Cancer.

  • Management of Squamous Cell Cancer of the Anal Canal
    EBS #2-8: March 2009
  • Follow-up of Patients with Curatively Resected Colorectal Cancer
    2-9 PG: January 2004 Update
  • Oral Capecitabine (XelodaTM) in the First-line Treatment of Metastatic Colorectal Cancer
    2-15 EBS: February 2005 Update
  • Use of Irinotecan in the Second-Line Treatment of Metastatic Colorectal Carcinoma
    2-16 PG: Update July 2004
  • Use of Irinotecan (Camptosar®, CPT-11) Combined with 5-Fluorouracil and Leucovorin (5FU/LV) as First-line Therapy for Metastatic Colorectal Cancer
    2-16b PG: February 2003 Update
  • Use of Raltitrexed (TomudexTM) in the Management of Metastatic Colorectal Carcinoma
    2-17 PG: February 2005 Update
  • The Role of Oxaliplatin Combined with 5-Fluorouracil and Folinic Acid in the First and Second-Line Treatment of Advanced Colorectal Cancer
    2-22 EBS: December 2006
  • The Role of Bevacizumab (Avastin TM ) Combined with Chemotherapy in the Treatment of Patients With Advanced Colorectal Cancer
    2-25 EBS: May 2008
  • Adjuvant Systemic Chemotherapy for Stage II and III Colon Cancer Following Complete Resection
    2-29 EBS: April 2008
    EBS #2-29 replaces Practice Guidelines #2-1 Adjuvant Therapy for Stage II Colon Cancer Following Complete Resection and #2-2 Adjuvant Therapy for Stage III Colon Cancer Following Complete Resection

Pancreatic Cancer

Esophageal

Gastric

  • Neoadjuvant or Adjuvant Therapy for Resectable Gastric Cancer
    2-14 PG Version 2.2000: May 2003 Update
    EBS #2-14 is scheduled to be updated in 2009.

The following EBS reports are in various stages of development and only their titles are available at this time:

  • The Role of Chemotherapy in Advanced Gastric Cancer (2-26 EBS)

Contact:

Contact:
Program in Evidence-Based Care (PEBC)
McMaster University, Henderson Site
60 (G) Wing, 2nd Floor
711 Concession Street
Hamilton, Ontario, Canada
L8V 1C3

Phone: 905.527.4322 ext. 42822
Fax: 905.526.6775
Email: ccopgi@mcmaster.ca
Last modified: Fri, Feb 19, 2010

Cancer Care Ontario visitor survey

Please help improve the quality of our website by answering 9 brief questions in our online survey. Would you like to participate?

YesNo